Table 2.

Univariable binary logistic regression analysis for hospitalization and mortality.

Outcome	Independent Factors	Odds Ratio	95% C.I. for Odds Ratio	p-Value
Hospitalization
	Age	1.076	1.064–1.089	<0.001
	Male sex	1.587	1.223–2.060	0.001
	DMT			<0.001
	ALEMTUZUMAB *	-	-	-
	AZATHIOPRINE *	0.455	0.152–1.365	0.160
	CLADRIBINE *	0.166	0.065–0.425	<0.001
	DMF *	0.197	0.129–0.300	<0.001
	FINGOLIMOD *	0.291	0.197–0.428	<0.001
	GLATIRAMER ACETATE *	0.208	0.125–0.344	<0.001
	INTERFERON *	0.143	0.089–0.231	<0.001
	NATALIZUMAB *	0.039	0.005–0.287	0.001
	OCRELIZUMAB *	0.584	0.288–1.183	0.135
	RITUXIMAB *	0.716	0.192–2.668	0.619
	TERIFLUNOMIDE *	0.276	0.157–0.455	<0.001
	Number of comorbidities			<0.001
	1 **	2.449	1.770–3.390	<0.001
	2 **	2.387	1.448–3.937	0.001
	3 **	6.989	4.240–11.522	<0.001
	4+ **	5.024	2.033–12.411	<0.001
	Partially or fully vaccinated ***	0.418	0.317–0.552	<0.001
Death due to COVID-19
	Age	1.122	1.084–1.161	<0.001
	Male sex	2.039	0.926–4.490	0.077
	DMT			0.091
	ALEMTUZUMAB *	-	-	-
	AZATHIOPRINE *	-	-	-
	CLADRIBINE *	0.331	0.042–2.607	0.294
	DMF *	0.156	0.043–0.565	0.005
	FINGOLIMOD *	0.276	0.095–0.803	0.018
	GLATIRAMER ACETATE *	0.092	0.012–0.717	0.023
	INTERFERON *	0.114	0.025–0.520	0.005
	NATALIZUMAB *	-	-	-
	OCRELIZUMAB *	-	-	-
	RITUXIMAB *	-	-	-
	TERIFLUNOMIDE *	0.311	0.068–1.420	0.132
	Number of comorbidities			<0.001
	1 **	5.915	2.266–15.439	<0.001
	2 **	3.702	0.778–17.626	0.100
	3 **	12.693	3.733–43.155	<0.001
	4+ **	21.155	4.237–105.633	<0.001
	Partially or fully vaccinated ***	0.490	0.211–1.141	0.098

* Compared to the None DMT category. ** Compared to the zero number of comorbidities category. *** Compared to the unvaccinated category.